Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models
BACKGROUND: Sulfasalazine (SSZ) is widely known as an xCT inhibitor suppressing CD44v9-expressed cancer stem-like cells (CSCs) being related to redox regulation. Cholangiocarcinoma (CCA) has a high recurrence rate and no effective chemotherapy. A recent report revealed high levels of CD44v9-positive cells in CCA patients. Therefore, a combination of drugs could prove a suitable strategy for CCA treatment via individual metabolic profiling.
METHODS: We examined the effect of xCT-targeted CD44v9-CSCs using sulfasalazine combined with cisplatin (CIS) or gemcitabine in CCA in vitro and in vivo models and did NMR-based metabolomics analysis of xenograft mice tumor tissues.
RESULTS: Our findings suggest that combined SSZ and CIS leads to a higher inhibition of cell proliferation and induction of cell death than CIS alone in both in vitro and in vivo models. Xenograft mice showed that the CD44v9-CSC marker and CK-19-CCA proliferative marker were reduced in the combination treatment. Interestingly, different metabolic signatures and significant metabolites were observed in the drug-treated group compared with the control group that revealed the cancer suppression mechanisms.
CONCLUSIONS: SSZ could improve CCA therapy by sensitization to CIS through killing CD44v9-positive cells and modifying the metabolic pathways, in particular tryptophan degradation (i.e., kynurenine pathway, serotonin pathway) and nucleic acid metabolism.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
---|---|
Enthalten in: |
Cancer & metabolism - 9(2021), 1 vom: 16. März, Seite 11 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Thanee, Malinee [VerfasserIn] |
---|
Links: |
---|
Themen: |
CD44v9 |
---|
Anmerkungen: |
Date Revised 23.03.2021 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1186/s40170-021-00249-6 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM322834880 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM322834880 | ||
003 | DE-627 | ||
005 | 20231225182902.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s40170-021-00249-6 |2 doi | |
028 | 5 | 2 | |a pubmed24n1076.xml |
035 | |a (DE-627)NLM322834880 | ||
035 | |a (NLM)33726850 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Thanee, Malinee |e verfasserin |4 aut | |
245 | 1 | 0 | |a Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 23.03.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a BACKGROUND: Sulfasalazine (SSZ) is widely known as an xCT inhibitor suppressing CD44v9-expressed cancer stem-like cells (CSCs) being related to redox regulation. Cholangiocarcinoma (CCA) has a high recurrence rate and no effective chemotherapy. A recent report revealed high levels of CD44v9-positive cells in CCA patients. Therefore, a combination of drugs could prove a suitable strategy for CCA treatment via individual metabolic profiling | ||
520 | |a METHODS: We examined the effect of xCT-targeted CD44v9-CSCs using sulfasalazine combined with cisplatin (CIS) or gemcitabine in CCA in vitro and in vivo models and did NMR-based metabolomics analysis of xenograft mice tumor tissues | ||
520 | |a RESULTS: Our findings suggest that combined SSZ and CIS leads to a higher inhibition of cell proliferation and induction of cell death than CIS alone in both in vitro and in vivo models. Xenograft mice showed that the CD44v9-CSC marker and CK-19-CCA proliferative marker were reduced in the combination treatment. Interestingly, different metabolic signatures and significant metabolites were observed in the drug-treated group compared with the control group that revealed the cancer suppression mechanisms | ||
520 | |a CONCLUSIONS: SSZ could improve CCA therapy by sensitization to CIS through killing CD44v9-positive cells and modifying the metabolic pathways, in particular tryptophan degradation (i.e., kynurenine pathway, serotonin pathway) and nucleic acid metabolism | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a CD44v9 | |
650 | 4 | |a Chemosensitivity | |
650 | 4 | |a Cholangiocarcinoma therapy | |
650 | 4 | |a Metabolic signature | |
650 | 4 | |a Sulfasalazine | |
700 | 1 | |a Padthaisong, Sureerat |e verfasserin |4 aut | |
700 | 1 | |a Suksawat, Manida |e verfasserin |4 aut | |
700 | 1 | |a Dokduang, Hasaya |e verfasserin |4 aut | |
700 | 1 | |a Phetcharaburanin, Jutarop |e verfasserin |4 aut | |
700 | 1 | |a Klanrit, Poramate |e verfasserin |4 aut | |
700 | 1 | |a Titapun, Attapol |e verfasserin |4 aut | |
700 | 1 | |a Namwat, Nisana |e verfasserin |4 aut | |
700 | 1 | |a Wangwiwatsin, Arporn |e verfasserin |4 aut | |
700 | 1 | |a Sa-Ngiamwibool, Prakasit |e verfasserin |4 aut | |
700 | 1 | |a Khuntikeo, Narong |e verfasserin |4 aut | |
700 | 1 | |a Saya, Hideyuki |e verfasserin |4 aut | |
700 | 1 | |a Loilome, Watcharin |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cancer & metabolism |d 2013 |g 9(2021), 1 vom: 16. März, Seite 11 |w (DE-627)NLM233104429 |x 2049-3002 |7 nnns |
773 | 1 | 8 | |g volume:9 |g year:2021 |g number:1 |g day:16 |g month:03 |g pages:11 |
856 | 4 | 0 | |u http://dx.doi.org/10.1186/s40170-021-00249-6 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 9 |j 2021 |e 1 |b 16 |c 03 |h 11 |